Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy
A high prevalence of HER3 expression was observed in pancreatic cancer patients after chemotherapy. Our findings indicate that HER3 is a potential therapeutic target for pancreatic cancer, deserving further clinical investigation.
Authors
- Satoshi Nara (ORCID: https://orcid.org/0000-0002-3516-8765)
- Tomoyuki Satake (ORCID: https://orcid.org/0000-0001-9445-7738)
- Chigusa Morizane
- Takuji Okusaka
- Maki Kobayashi (ORCID: https://orcid.org/0000-0001-5920-5906)
- Tomoya Kakegawa
- Nobuyoshi Hiraoka (ORCID: https://orcid.org/0000-0003-4215-4385)
- Kumiko Koyama (ORCID: https://orcid.org/0000-0002-2090-7860)
- Mao Okada
- Mariko Nishioka
- Minoru Esaki (ORCID: https://orcid.org/0000-0002-9631-6178)
Institutions
- Daiichi-Sankyo (Japan) (JP)
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/cam4.70474
- Citations
- 6
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Daiichi Sankyo Europe